Myriad Genetics Inc (MYGN) Stock Analysis

Myriad Genetics Inc (MYGN) is a publicly traded company in the HEALTHCARE sector. It trades at $4.31, carries a market capitalization of $404.24M. This page summarizes the public market data, fundamentals, and frequently asked questions for MYGN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DIAGNOSTICS & RESEARCH

Exchange: NASDAQ

Key Metrics

• Price: $4.31
• Market Cap: $404.24M
• EPS: $-4.31
• 52-Week High: $8.59
• 52-Week Low: $3.53

Market Sentiment

Myriad Genetics Inc currently has a Bullish sentiment score of 0.19.

About Myriad Genetics Inc

Myriad Genetics, Inc. is a prominent molecular diagnostics firm based in Salt Lake City, Utah, renowned for its innovative genetic testing solutions that support predictive, personalized, and prognostic medicine. The company specializes in key areas such as oncology, hereditary cancer, and reproductive health, empowering healthcare professionals to make data-driven decisions tailored to individual patients. With a strong focus on advancing genetic medicine, Myriad is dedicated to expanding it...

GNG Research Analysis

GNG Research scores Myriad Genetics Inc (MYGN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MYGN.

Frequently Asked Questions

Does MYGN pay dividends?

Myriad Genetics Inc (MYGN) does not currently pay a regular dividend.

What is MYGN's market cap?

Myriad Genetics Inc (MYGN) has a market capitalization of $404.24M with a current stock price of $4.31.